Table 3. Breakdown of regimen options in... | American Society of Hematology

Table 3.

Breakdown of regimen options in the relapsed setting with subgroup analyses of older/frail populations

Study	Regimen	Median prior lines of Tx (range)	ORR, %	≥VGPR, %	PFS	OS	Frail/elderly subgroup analysis	No. (%) in triplet group	PFS	OS
IMiD based
ASPIRE [Siegel et al, 2018]⁹⁷	KRd	2 (1-3)	87.1	69.9	26.1 mo^*	48.3 mo^*	Facon et al, 2020⁹⁸	93 (23) frail by IMWG frailty index	24.1 mo	36.4 mo
TOURMALINE-MM1 [Richardson et al, 2021]⁹⁹	IxaRd	[1 prior, 62%; 2-3 prior, 38%]^*	79^*	52^*	20.6 mo	53.6 mo^*	Richardson et al, 2021⁹⁹	47 (13) >75 y	—	36.9 mo^*
POLLUX [Bahlis et al, 2020]¹⁰⁰	DRd	1 (1-11)^*	92.9^*	80.4^*	44.5 mo^*	@12 mo: 92.1%	Mateos et al, 2020¹⁰¹	29 (10) ≥75 y	28.9 mo	Data immature
ELOQUENT-2 [Dimopoulos et al, 2020]¹⁰²	EloRd	2 (1-4)	79	33	19.4 mo^*	48.3 mo^*	Dimopoulos et al, 2020¹⁰²	68 (21) ≥75 y	—	48.5 mo
ELOQUENT-3 [Dimopoulos et al, 2021]¹⁰³	EloPd	3 (2-8)	53	20	10.3 mo	@12 mo: 79%^*				—
APOLLO [Dimopoulos et al, 2021]¹⁰⁴	DPd	2 (1-5)	69	51	12.4 mo	Data immature	Dimopoulos et al, 2021¹⁰⁴	88 (58) ≥65 y	14.2 mo	Data immature
ICARIA-MM [Attal et al, 2019]¹⁰⁵	IsaPd	3 (2-4)	60	32	11.5 mo	@12 mo: 72%	Schjesvold et al, 2021¹⁰⁶	48 (31.2) frail by Facon score	9.0 mo	@12 mo: 66.9%
PI based
OPTIMISMM [Richardson et al, 2019]¹⁰⁷	PVd	[1 prior, 40%; 2+ prior, 42%]	82.2	53	11.2 mo	Data immature	Rocafiguera et al, 2022¹⁰⁸	93 (33) frail by IMWG frailty index	9.7 mo	—
PANORAMA1 [San-Miguel et al, 2016]¹⁰⁹	FVd	[1 prior, 51%; 2-3 prior, 49%]	60.7	28	12.0 mo	40.3 mo^*	San-Miguel et al, 2016¹⁰⁹	162 (42) ≥65 y	—	37.3 mo^*
BOSTON [Grosicki et al, 2020]¹¹⁰	SeliVd	2 (1-3)	76.4	45	13.9 mo	Data immature	Auner et al¹¹¹	66 (34) frail and 109 (56) >65 y	13.93 mo for frail cohort	Data immature
CASTOR [Mateos et al, 2020]¹¹²	DVd	2 (1-9)	85^*	63^*	16.7 mo^*	Data immature	Mateos et al, 2020¹⁰¹	23 (9) ≥75 y	17.9 mo^*	Data immature
CANDOR [Usmani et al, 2022]¹¹³	DKd	[1 prior, 46%; 2-3 prior, 54%]	84^*	69^*	28.6 mo^*	Data immature	Usmani et al, 2022¹¹³	134 (43) >65 y	25.9 mo^*	Data immature
IKEMA [Moreau et al, 2021]¹¹⁴	IsaKd	2 (1-2)	87	73	@24 mo: 69%	Data immature	Facon et al¹¹⁵	52 (28.5) ≥70 y	NR (24 mo PFS ~72%)	Data immature

Study	Regimen	Median prior lines of Tx (range)	ORR, %	≥VGPR, %	PFS	OS	Frail/elderly subgroup analysis	No. (%) in triplet group	PFS	OS
IMiD based
ASPIRE [Siegel et al, 2018]⁹⁷	KRd	2 (1-3)	87.1	69.9	26.1 mo^*	48.3 mo^*	Facon et al, 2020⁹⁸	93 (23) frail by IMWG frailty index	24.1 mo	36.4 mo
TOURMALINE-MM1 [Richardson et al, 2021]⁹⁹	IxaRd	[1 prior, 62%; 2-3 prior, 38%]^*	79^*	52^*	20.6 mo	53.6 mo^*	Richardson et al, 2021⁹⁹	47 (13) >75 y	—	36.9 mo^*
POLLUX [Bahlis et al, 2020]¹⁰⁰	DRd	1 (1-11)^*	92.9^*	80.4^*	44.5 mo^*	@12 mo: 92.1%	Mateos et al, 2020¹⁰¹	29 (10) ≥75 y	28.9 mo	Data immature
ELOQUENT-2 [Dimopoulos et al, 2020]¹⁰²	EloRd	2 (1-4)	79	33	19.4 mo^*	48.3 mo^*	Dimopoulos et al, 2020¹⁰²	68 (21) ≥75 y	—	48.5 mo
ELOQUENT-3 [Dimopoulos et al, 2021]¹⁰³	EloPd	3 (2-8)	53	20	10.3 mo	@12 mo: 79%^*				—
APOLLO [Dimopoulos et al, 2021]¹⁰⁴	DPd	2 (1-5)	69	51	12.4 mo	Data immature	Dimopoulos et al, 2021¹⁰⁴	88 (58) ≥65 y	14.2 mo	Data immature
ICARIA-MM [Attal et al, 2019]¹⁰⁵	IsaPd	3 (2-4)	60	32	11.5 mo	@12 mo: 72%	Schjesvold et al, 2021¹⁰⁶	48 (31.2) frail by Facon score	9.0 mo	@12 mo: 66.9%
PI based
OPTIMISMM [Richardson et al, 2019]¹⁰⁷	PVd	[1 prior, 40%; 2+ prior, 42%]	82.2	53	11.2 mo	Data immature	Rocafiguera et al, 2022¹⁰⁸	93 (33) frail by IMWG frailty index	9.7 mo	—
PANORAMA1 [San-Miguel et al, 2016]¹⁰⁹	FVd	[1 prior, 51%; 2-3 prior, 49%]	60.7	28	12.0 mo	40.3 mo^*	San-Miguel et al, 2016¹⁰⁹	162 (42) ≥65 y	—	37.3 mo^*
BOSTON [Grosicki et al, 2020]¹¹⁰	SeliVd	2 (1-3)	76.4	45	13.9 mo	Data immature	Auner et al¹¹¹	66 (34) frail and 109 (56) >65 y	13.93 mo for frail cohort	Data immature
CASTOR [Mateos et al, 2020]¹¹²	DVd	2 (1-9)	85^*	63^*	16.7 mo^*	Data immature	Mateos et al, 2020¹⁰¹	23 (9) ≥75 y	17.9 mo^*	Data immature
CANDOR [Usmani et al, 2022]¹¹³	DKd	[1 prior, 46%; 2-3 prior, 54%]	84^*	69^*	28.6 mo^*	Data immature	Usmani et al, 2022¹¹³	134 (43) >65 y	25.9 mo^*	Data immature
IKEMA [Moreau et al, 2021]¹¹⁴	IsaKd	2 (1-2)	87	73	@24 mo: 69%	Data immature	Facon et al¹¹⁵	52 (28.5) ≥70 y	NR (24 mo PFS ~72%)	Data immature

Data per updated analysis; otherwise, per initial publication.

DKd, daratumumab, carfilzomib, dexamethasone; DPd, daratumumab, pomalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; DVd, daratumumab, bortezomib, dexamethasone; EloPd, elotuzumab, pomalidomide, dexamethasone; EloRd, elotuzumab, lenalidomide, dexamethasone; FVd, panobinostat, bortezomib, dexamethasone; IsaKd, isatuximab, carfilzomib, dexamethasone; IsaPd, isatuximab, pomalidomide, dexamethasone; IxaRd, ixazomib, lenalidomide, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; NR, not reported; Pd, pomalidomide; PI, proteosome inhibitor; PVd, pomalidomide, bortezomib, dexamethasone; SeliVd, selinexor, bortezomib, dexamethasone; Tx, treatment; VGPR, very good partial response.

View Large

This Feature Is Available To Subscribers Only